Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2015
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Metabolic syndrome; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 26 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov record.
- 02 Dec 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrial.gov record.